MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments

Core Viewpoint - MaxCyte, Inc. has announced the acquisition of SeQure Dx, enhancing its capabilities in cell and gene therapy development and commercialization [1][2] Group 1: Acquisition Details - MaxCyte acquired SeQure Dx for an initial cash consideration of $4.5 million, with potential contingent payments up to$2.5 million based on revenue targets [6] - SeQure Dx generated approximately $1.7 million in revenue and incurred a loss of about$6.5 million in 2024 [6] - The acquisition is expected to be accretive to MaxCyte's revenue growth and improve operational efficiencies [2][7] Group 2: Strategic Importance - The acquisition strengthens MaxCyte's service offerings for ex vivo and in vivo cell and gene therapy developers, providing innovative tools and services from early R&D to commercialization [2][3] - SeQure Dx specializes in precise editing confirmation and risk assessment for off-target effects, crucial for regulatory success in gene therapies [3][4] - The integration of SeQure Dx is aimed at enhancing safety and precision in cell therapies, aligning with MaxCyte's commitment to advancing cell engineering [4][5] Group 3: Company Background - SeQure Dx, co-founded by Dr. Keith Joung, emerged from stealth mode in late 2022 and offers a comprehensive portfolio of evaluation assays for off-target risk validation [4][10] - MaxCyte has over 25 years of experience in cell engineering, focusing on developing platforms that support the cell therapy market [9]